semaglutide study weight loss How Long Do You Stay on for Loss? Guide TrimRX | Semaglutide Weight Loss

GLP1 agonists like Semaglutide, Liraglutide may increase risk of pancreatitis, gastroparesis and bowel obstruction US: Researchers at University of British Columbia have found in a new study that that use of glucagon-like peptide-1 agonists for weight loss compared with use of bupropion-naltrexone was associated with increased risk of pancreatitis, gastroparesis, and bowel obstruction but not biliary disease

The study was funded by Novo Nordisk, which designed and oversaw the trial

Medscape article Semaglutide Linked to Cause of Vision Loss (Open access) Forbes article Using Ozempic Or Wegovy Could Raise Risk For Rare Form Of Blindness, Study Suggests See more from MedicalBrief archives: US study finds serious side effects from weight-loss drugs Patients felled by weight-loss drugs side effects Weight loss drug trial suggests significant heart benefit CVD benefits from weight-loss drugs a game-changer

Oral semaglutide appeals to needle-averse patients, but it comes with trade-offs